xmlui.ArtifactBrowser.ConfigurableBrowse.title.metadata.subject_decs
Ara mostrant els elements 1-1 d 1
-
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
(American Association for Cancer Research, 2022-02-01)